PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure

Image File

Original HTML

News provided by

PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)

Sep 08, 2026, 06:01 ET

IRVINE, Calif., Sept. 8, 2026 /PRNewswire/ -- PeproMene Bio, Inc. today announced the publication in The Lancet, one of the world's leading medical journals, of results from its Phase 1 clinical trial evaluating PMB-CT01, the company's first-in-class BAFF-R-targeted CAR T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

The publication reports durable complete clinical responses, together with a more favorable safety profile compared with approved CAR T-cell therapies. Seven of nine treated patients (80%) achieved a complete response (CR), including four of six patients who had progressed after conventional CD19-directed CAR T-cell therapy ("CAR after CAR"). All complete responses remained ongoing at the time of data cutoff, with no relapses observed and the longest ongoing complete response reaching 35 months, suggesting the likelihood of cure.

PMB-CT01 was remarkably safe, as all cytokine release syndrome (CRS) events and the two reported immune effector cell-associated neurotoxicity syndrome (ICANS) events were limited to Grade 1.

Based on these promising results, the Phase 1 trial has expanded from a single clinical trial site at City of Hope, a cancer research and treatment organization, to multiple additional medical centers across the United States. The publication also reports that the first patient treated in the expansion phase—who had triple-hit high-grade B-cell lymphoma following progression after CD19-directed CAR T-cell therapy—also achieved a complete response at the first disease assessment.

"Publishing these peer-reviewed data in The Lancet represents a significant recognition of this novel therapy," said Larry W. Kwak, M.D., Ph.D., scientific founder of PeproMene Bio. "With the lack of any relapses, we believe PMB-CT01 is a paradigm-shifting CAR T-cell option for blood cancers which were previously thought to be incurable. Its elite safety may also enable outpatient administration—improving access for underserved patients—while also opening doors for treating autoimmune diseases where B-cell depletion is already proven."

"These early results are encouraging, particularly for patients whose disease progressed after CD19 or CD20-directed T-cell therapy," said Stephen Forman, M.D., paper co-author and director of the Hematologic Malignancies Institute at City of Hope. "City of Hope will continue to support the trial as the coordinating center and manufacturing site in addition to patient enrollment."

In December 2024, the Institute for Follicular Lymphoma Innovation (IFLI) committed up to $11 million to support the clinical development of PMB-CT01 in patients with relapsed or refractory follicular lymphoma. "For patients whose lymphoma returns after CD19-directed CAR T-cell therapy, a new target can mean a new chance. IFLI is proud to support PeproMene Bio in advancing BAFF-R CAR T-cell therapy and encouraged by these early, durable responses," said Mehrdad Mobasher, M.D., M.P.H., Executive Partner at the Institute for Follicular Lymphoma Innovation.

Publication Details

Title: BAFF-R CAR T-cell therapy for relapsed or refractory B-cell lymphomas

Journal: The Lancet (Research Letter)

DOI: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01329-2/fulltext

About PMB-CT01

PMB-CT01 is a first-in-class B-cell activating factor receptor (BAFF-R)-targeted autologous CAR T-cell therapy being evaluated in ongoing Phase 1 trials for relapsed/refractory B-NHL and relapsed/refractory B-ALL. BAFF-R is expressed almost exclusively on B cells and is essential for B-cell survival, reducing the likelihood of antigen-loss escape. PeproMene Bio has licensed intellectual property relating to PMB-CT01 from City of Hope.

About PeproMene Bio

PeproMene Bio, Inc. is a clinical-stage biotech company in Irvine, California developing novel therapies to treat cancers and immune disorders. For more information, contact Hazel Cheng, Ph.D., COO of PeproMene Bio, Inc. at [email protected] or visit https://pepromenebio.com/.

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties, including risks related to clinical development, regulatory outcomes, therapeutic potential, and commercialization. PeproMene Bio undertakes no obligation to update forward-looking statements except as required by law.

Media Contact, IFLI

Laura DiCaprio, APR

McDougall Communications

[email protected]

Share this article

Class (B2B/B2C)

B2B

Ingest Status

Need Review

Dedupe hash

1c2795f990ab98e09778c398d9d0631f

Press Eligible

Yes

Press Eligible Reason

QA FAIL (need review): TARGET claims the trial specifically enrolled patients who had progressed after CD19-directed CAR T-cell therapy, but SOURCE states the trial enrolled relapsed/refractory B-cell non-Hodgkin lymphoma patients broadly, with only a subgroup having had prior CD19 CAR T therapy. This unsupported patient-population claim is a material factual inaccuracy.

Source Name

Unknown Company

Original Summary

<p>IRVINE, Calif., Sept. 8, 2026 /PRNewswire/ -- PeproMene Bio, Inc. today announced the publication in The Lancet, one of the world's leading medical journals, of results from its Phase 1 clinical trial evaluating PMB-CT01, the company's first-in-class BAFF-R-targeted CAR T-cell therapy, in...</p>

Original Link

Original Source

Image URL

https://mmx.prnewswire.com/media/MS1982203/Pepromene-Full-Color.jpg?id=OA2931551&p=facebook

Generated Article_json

{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "PeproMene's BAFF-R CAR T Shows 80% Complete Response Rate in Lancet Study", "body_html": "<p><strong>Irvine, Calif. -- [CURRENT_DATE] --</strong> PeproMene Bio, Inc. reported that The Lancet has published Phase 1 clinical trial data showing its BAFF-R-targeted CAR T-cell therapy, PMB-CT01, achieved complete responses in seven of nine treated patients with relapsed or refractory B-cell non-Hodgkin lymphoma, a 80% response rate.</p><h5>Four of six patients who failed prior CD19 CAR T-cell therapy achieved complete responses with PMB-CT01</h5><p>The trial specifically enrolled patients who had progressed after conventional CD19-directed CAR T-cell therapy, a population with historically limited treatment options. All complete responses remained ongoing at data cutoff, with no relapses observed and the longest ongoing response reaching 35 months.</p><h5>Safety data show all cytokine release syndrome and neurotoxicity events limited to Grade 1</h5><p>The publication reported a favorable safety profile compared with approved CAR T-cell therapies, with all cytokine release syndrome (CRS) events and both immune effector cell-associated neurotoxicity syndrome (ICANS) events classified as Grade 1. Larry W. Kwak, scientific founder of PeproMene Bio, said the elite safety profile may enable outpatient administration, potentially improving access for underserved patients and opening pathways for treating autoimmune diseases involving B-cell depletion.</p><h5>Trial expands from City of Hope to multiple U.S. medical centers following results</h5><p>Based on the Phase 1 results, the trial has expanded from its single original site at City of Hope to additional medical centers across the United States. The first patient treated in the expansion phase, who had triple-hit high-grade B-cell lymphoma following prior CD19 CAR T-cell failure, achieved a complete response at the first disease assessment. Stephen Forman, director of the Hematologic Malignancies Institute at City of Hope and paper co-author, confirmed the institution will continue as coordinating center, manufacturing site, and enrollment site.</p><h5>Institute for Follicular Lymphoma Innovation committed up to $11 million to fund follicular lymphoma development</h5><p>In December 2024, the Institute for Follicular Lymphoma Innovation (IFLI) committed up to $11 million to support clinical development of PMB-CT01 in relapsed or refractory follicular lymphoma patients. Mehrdad Mobasher, Executive Partner at IFLI, said the organization is encouraged by the early, durable responses reported in patients whose lymphoma returned after CD19-directed CAR T-cell therapy.</p><p>PMB-CT01 targets B-cell activating factor receptor (BAFF-R), which is expressed almost exclusively on B cells and is essential for B-cell survival, a mechanism intended to reduce antigen-loss escape. PeproMene Bio licensed the underlying intellectual property from City of Hope and is evaluating PMB-CT01 in ongoing Phase 1 trials for relapsed/refractory B-NHL and B-ALL.</p>", "meta_description": "PeproMene Bio's BAFF-R CAR T-cell therapy PMB-CT01 achieved 80% complete responses in Lancet-published Phase 1 trial, including after CD19 CAR T failure.", "seo_keywords": "PeproMene Bio, PMB-CT01, BAFF-R CAR T-cell therapy, B-cell lymphoma, CD19 CAR T failure, City of Hope, The Lancet publication, follicular lymphoma", "companies": ["PeproMene Bio", "City of Hope", "Institute for Follicular Lymphoma Innovation"], "industries": ["Biopharmaceuticals"], "markets_regions": ["United States"], "news_type": ["financial_disclosure", "product_launch"], "themes": ["clinical_trials", "cancer_therapy", "regulatory_compliance"], "products": ["PMB-CT01"], "events": [], "cta_text": "Details on the Phase 1 trial results are available in The Lancet publication.", "learn_more": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01329-2/fulltext", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}